Swipe om te navigeren naar een ander artikel
The online version of this article (doi:10.1007/s11136-015-0950-6) contains supplementary material, which is available to authorized users.
Improved survival for men with prostate cancer has led to increased attention to factors influencing quality of life (QOL). As protein levels of vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF-1) have been reported to be associated with QOL in people with cancer, we sought to identify whether single-nucleotide polymorphisms (SNPs) of these genes were associated with QOL in men with prostate cancer.
Multiple linear regression of two data sets (including approximately 750 men newly diagnosed with prostate cancer and 550 men from the general population) was used to investigate SNPs of VEGF and IGF-1 (10 SNPs in total) for associations with QOL (measured by the SF-36v2 health survey).
Men with prostate cancer who carried the minor ‘T’ allele for IGF-1 SNP rs35767 had higher mean Role-Physical scale scores (≥0.3 SD) compared to non-carriers (p < 0.05). While this association was not identified in men from the general population, one IGF-1 SNP rs7965399 was associated with higher mean Bodily Pain scale scores in men from the general population that was not found in men with prostate cancer. Men from the general population who carried the rare ‘C’ allele had higher mean Bodily Pain scale scores (≥0.3 SD) than non-carriers (p < 0.05).
Through identifying SNPs that are associated with QOL in men with prostate cancer and men from the general population, this study adds to the mapping of complex interrelationships that influence QOL and suggests a role for IGF-I in physical QOL outcomes. Future research may identify biomarkers associated with increased risk of poor QOL that could assist in the provision of pre-emptive support for those identified at risk.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Sprangers, M. A., Sloan, J. A., Veenhoven, R., Cleeland, C. S., Halyard, M. Y., Abertnethy, A. P., et al. (2009). The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Research and Human Genetics, 12(3), 301–311. PubMedCentralPubMedCrossRef
Sprangers, M. A., Sloan, J. A., Barsevick, A., Chauhan, C., Dueck, A. C., Raat, H., et al. (2010). Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Quality of Life Research, 19(10), 1395–1403. PubMedCentralPubMedCrossRef
Peters, C. A., Stock, R. G., Cesaretti, J. A., Atencio, D. P., Peters, S., Burri, R. J., et al. (2008). TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 70(3), 752–759. CrossRef
De Langhe, S., De Ruyck, K., Ost, P., Fonteyne, V., Werbrouck, J., De Meerleer, G., et al. (2013). Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFbeta1 gene. International Journal of Radiation Oncology Biology Physics, 85(2), 393–399. CrossRef
Meyerhardt, J. A., Sloan, J. A., Sargent, D. J., Goldberg, R. M., Pollak, M., Morton, R. F., et al. (2005). Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiology, Biomarkers and Prevention, 14(6), 1402–1410. PubMedCrossRef
Health Assessment Lab - Medical Outcomes Trust and QualityMetric Incorporated (2003). SF- 36v2 Health Survey, IQOLA SF36v2 Standard, English (Australia).
Fayers, P., & Machin, D. (2007). Quality of life: The Assessment, Analysis and Interpretation of Patient-reported Outcomes (Vol. Book, Whole): Wiley. CrossRef
Ware, J. E., Kosinski, M., Bjorner, J., Turner-Bowker, D., Gandek, B., & Maruish, M. (2007). User’s manual for the SF-36v2 health survey (2nd ed.). Lincoln: QualityMetric.
Lose, F., Nagle, C. M., O’Mara, T., Batra, J., Bolton, K. L., Song, H., et al. (2010). Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecologic Oncolology, 119(3), 479–483. CrossRef
Edge, S. B., & American Joint Committee on, C. (2010). AJCC cancer staging manual (Vol. Book, Whole). New York: Springer.
Patel, A. V., Cheng, I., Canzian, F., Le Marchand, L., Thun, M. J., Berg, C. D., et al. (2008). IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE, 3(7), e2578. PubMedCentralPubMedCrossRef
Kostek, M. C., Devaney, J. M., Gordish-Dressman, H., Harris, T. B., Thompson, P. D., Clarkson, P. M., et al. (2010). A polymorphism near IGF1 is associated with body composition and muscle function in women from the health, aging, and body composition study. European Journal of Applied Physiology, 110(2), 315–324. PubMedCentralPubMedCrossRef
Ben-Zaken, S., Meckel, Y., Nemet, D., & Eliakim, A. (2013). Can IGF-I polymorphism affect power and endurance athletic performance? Growth Hormone & IGF Research, 23(5), 175–178. CrossRef
- Association between single-nucleotide polymorphisms in growth factor genes and quality of life in men with prostate cancer and the general population
Kimberly E. Alexander
Amanda B. Spurdle
Tracy A. O’Mara
Robert A. Gardiner
Joanne F. Aitken
Judith A. Clements
- Springer International Publishing